Emilia Cocorocchio et al., Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience. Ecancermedicalscience

E Cocorocchio1, S Gandini2, S Alfieri1, A Battaglia1, E Pennacchioli3, G Tosti4, G Spadola4, M Barberis5, M Di Leo1, C Riviello1, L Pala1, A Intelisano3, C Martinoli1 and PF Ferrucci1

1Medical Oncology of Melanoma and Sarcoma Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy
2Biostatistics Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy
3Sarcoma Unit, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy
4Dermatoncological Surgery Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy
5Pathology Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy

Abstract:

Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS and OS were seven and 17 months, respectively (median follow-up: 8.5 months). Increased risk of progression was found in pts with elevated LDH, ECOG PS >1 and more than two metastatic sites. Grade 3–4 adverse events were recorded in 4 pts. In this retrospective analysis, Dabrafenib confirmed its role as the standard clinical option in metastatic melanoma pts.

Read the complete publication at this link

Products
Request information

Please insert your email address below, we will contact you soon.

I confirm that I have read the information on the personal data management.

I agree to the processing of my personal data according to the above mentioned information

*Both options must be selected



2017-08-08T12:38:35+00:00